Chemotherapy News and Research

Latest Chemotherapy News and Research

Effective chemotherapeutic drug may induce permanent hearing loss in Cockayne syndrome individuals

The chemotherapy drug cisplatin can kill cancer, but it can also cause permanent hearing loss.

19 May 2016

Neurotoxic effects of chemotherapy may impair cognitive function in young ALL patients

The neurotoxic effects of chemotherapeutic drugs on the developing brains of young patients with acute lymphoblastic leukemia (ALL) may impair their cognitive functioning by disrupting the formation of neural networks that connect brain regions and transfer information.

19 May 2016

Empowering mobile health: an interview with Dr Rich Khatib and Dan Vahdat

overview of Medopad and how you deliver patient information to mobile devices? Medopad is a mobile health technology company. We focus on developing software within the mobile health industry. Mobile health, from our perspective, is an industry that really was invented with the iPad.

18 May 2016

Research on immune system sets stage for novel approach to cancer immunotherapy

Basic research into the dual nature of certain immune system cells has set the stage for a new approach to cancer immunotherapy that avoids some of the shortcomings associated with other methods, scientists at Dana-Farber Cancer Institute report in a new study in the Proceedings of the National Academy of Sciences.

17 May 2016

Novel therapeutic approach to treat leukaemia patients

Cancer cells have an abnormal cell division and survival machinery - they grow faster than they die. For their permanent development, they produce an excess of growth factors and nutrients and block the body's own safety mechanisms.

17 May 2016

Experimental hepatitis C drug slows down development of Zika in mice

Virologists from KU Leuven, Belgium, have shown that an experimental antiviral drug against hepatitis C slows down the development of Zika in mice. The research team was led by Professor Johan Neyts from the Laboratory of Virology and Chemotherapy.

17 May 2016

Carol Fabian inducted into KU Women's Hall of Fame for contributions to breast cancer research

Among the women inducted into the University of Kansas Hall of Fame on April 14, 2016, was Carol Fabian, MD. Fabian, a professor of medicine at the University of Kansas Medical Center and director of the Breast Cancer Prevention Center at The University of Kansas Cancer Center, is a nationally recognized oncologist and a pioneer in in the field of breast cancer research.

17 May 2016

Arkin Holdings and Primera Capital lead investment of $13M in BioSight

BioSight, Ltd, an Israeli pharmaceutical development company focused on the development of innovative chemotherapy pro-drugs with reduced toxicity, announced today the closing of an investment of $13M led by the Mori Arkin's pharmaceutical investment firm, Arkin Holdings, and the US based venture firm Primera Capital. Proceeds of the financing will be used to fund a multi-center phase IIb clinical trial with the company's lead product, Astarabine™, for the treatment of AML.

16 May 2016

Texas to host first-ever delegation of UK’s medical technology companies

Texas is about to play host to the first ever delegation of innovative medical technology companies from the United Kingdom.

From Paxman 13 May 2016

Single breath-hold for more than five minutes could make targeted radiotherapy feasible

Researchers at the University of Birmingham working with clinical teams at University Hospitals Birmingham NHS Foundation Trust have successfully shown for the first time that breast cancer patients can be trained to achieve single prolonged breath holds of over five minutes, opening the door for targeted radiotherapy to be administered with just one dose in each daily session.

12 May 2016

Mitoxantrone drug users more likely to develop colorectal cancer

The multiple sclerosis (MS) drug mitoxantrone may be associated with an increased risk of colorectal cancer, according to a study published in the May 11, 2016, online issue of Neurology, the medical journal of the American Academy of Neurology. Mitoxantrone suppresses the immune system.

12 May 2016

University of Glasgow-led study could lead to improved treatments for lymphoma, other cancers

A study by scientists at the University of Glasgow, which reveals the critical role a common cancer-associated gene plays in lymphoma development, could lead to improved treatments for a range of cancers.

11 May 2016

Scottish women with metastatic carcinoma of cervix could now benefit from Avastin treatment

From today, women in Scotland with an advanced and incurable form of cervical cancer could benefit from the targeted treatment Avastin, which has been given the green light by the Scottish Medicines Consortium (SMC) for routine use on the NHS.

11 May 2016

Simultaneous DNA, RNA and protein analysis to enhance cancer immunology studies: an interview with Dr Joseph Beechem

Cancer immunology is all about how your immune cells are going to fight and kill your tumor cells. If you look at the pure genetic code of a T-cell that's going to kill your tumor compared to the same cell that has been “put-to-sleep” (by the tumor), the pure genetic DNA content of those two cells are identical.

From NanoString Technologies 11 May 2016

Sophisticated technology helps model and simulate optimal dose for pediatric ependymoma patients

St. Jude Children's Research Hospital scientists have used sophisticated pharmacologic modeling and simulation to translate preclinical findings into a successful phase I clinical trial of a chemotherapy agent for treatment of ependymoma. The research marked the first time the approach has been used to calculate drug doses for a clinical trial in pediatric brain tumor patients.

10 May 2016

Pathogen-selective approach to antibiotic development less disruptive to gut microbiome

St. Jude Children's Research Hospital scientists report the first evidence that a pathogen-specific antibiotic was less disruptive to the gut microbiome than broad-spectrum antibiotics.

10 May 2016

Study links lower concentration of heat-shock proteins to recurrence of thymic tumors

In most cases, tumors of the thymus gland are removed by surgical resection. However, they recur after a few years in up to one third of patients. A research team headed up by thoracic surgeon Bernhard Moser of the Thoracic Surgery Department at MedUni Vienna has successfully demonstrated that these tumors form heat-shock proteins. The lower the concentration of these proteins, the more quickly tumors recur. The study has been published in the leading journal Scientific Reports.

10 May 2016

MUSC Hollings Cancer Center receives $8.9 million grant to explore signaling in sphingolipids

The Medical University of South Carolina's Hollings Cancer Center received an $8.9 million grant from the National Cancer Institute designed to foster collaboration across clinical and laboratory research for the study of signaling in sphingolipids, a class of lipids known to be involved in the growth of solid tumor cancers.

10 May 2016

Experimental therapy stops glioblastoma, high-grade gliomas in human cells and mouse models

Researchers report in the journal Cancer Cell an experimental therapy that in laboratory tests on human cells and mouse models stops aggressive, treatment-resistant and deadly brain cancers called glioblastoma and high-grade gliomas.

10 May 2016

Gene therapy could be potential treatment for neuropathic pain in cancer patients

A study providing new information about neuropathic pain afflicting some 90 percent of cancer patients who have had nerve damage caused by tumors, surgery, chemotherapy or radiation indicates gene therapy as a possible treatment.

6 May 2016

Chemotherapy News and Research

Latest Chemotherapy News and Research

Effective chemotherapeutic drug may induce permanent hearing loss in Cockayne syndrome individuals

Neurotoxic effects of chemotherapy may impair cognitive function in young ALL patients

Empowering mobile health: an interview with Dr Rich Khatib and Dan Vahdat

Research on immune system sets stage for novel approach to cancer immunotherapy

Novel therapeutic approach to treat leukaemia patients

Experimental hepatitis C drug slows down development of Zika in mice

Carol Fabian inducted into KU Women's Hall of Fame for contributions to breast cancer research

Arkin Holdings and Primera Capital lead investment of $13M in BioSight

Texas to host first-ever delegation of UK’s medical technology companies

Single breath-hold for more than five minutes could make targeted radiotherapy feasible

Mitoxantrone drug users more likely to develop colorectal cancer

University of Glasgow-led study could lead to improved treatments for lymphoma, other cancers

Scottish women with metastatic carcinoma of cervix could now benefit from Avastin treatment

Simultaneous DNA, RNA and protein analysis to enhance cancer immunology studies: an interview with Dr Joseph Beechem

Sophisticated technology helps model and simulate optimal dose for pediatric ependymoma patients

Pathogen-selective approach to antibiotic development less disruptive to gut microbiome

Study links lower concentration of heat-shock proteins to recurrence of thymic tumors

MUSC Hollings Cancer Center receives $8.9 million grant to explore signaling in sphingolipids

Experimental therapy stops glioblastoma, high-grade gliomas in human cells and mouse models

Gene therapy could be potential treatment for neuropathic pain in cancer patients

Cancer Research - Second Edition eBook

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Chemotherapy News and Research

Latest Chemotherapy News and Research

Cancer Research - Second Edition eBook

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Newsletters you may be interested in